Podcasts about sao paulo

F1TV lead commentator Alex Jacques and Brazilian commentator Felipe Giaffone join Tom Clarkson in the Interlagos paddock to analyse an eventful race in Brazil. Converting two pole positions into Grand Prix and Sprint wins, Lando Norris produced a perfect weekend to move 24 points clear of teammate Oscar Piastri at the top of the standings. With just three rounds left of the 2025 season, does Lando have one hand on the title now? What did Alex and Felipe make of Oscar's 10-second penalty? And how will the Australian be feeling after losing more ground in the championship? After his sensational win from P17 in Sao Paulo last year, Max Verstappen fought back in emphatic style again – this time from the pitlane to P3. How did he and Red Bull execute that incredible comeback after such a difficult qualifying session? Despite that remarkable recovery, Max lost more ground on Lando, but did close the gap to Oscar, so where do his hopes of becoming a five-time World Champion this season lie now? Plus, the guys also reflect on impressive performances from Kimi Antonelli, Ollie Bearman and Liam Lawson, a challenging first home race for Gabriel Bortoleto, and a very disappointing double DNF for Ferrari. Listen to more official F1 podcasts In-depth interviews with F1's biggest stars on F1 Beyond The Grid Your F1 questions answered by the experts on F1 Explains Experience the 2025 F1 title fight Book your seat for a Grand Prix this season at tickets.formula1.com

Championship over in Interlagos? It's definitely on the cards… After a commanding weekend from Lando Norris in Brazil, it's one hand on the championship for the Brit.Join Ruby Price, Owain Meford and Jawad Yaqub for Grid Talk's review of the 2025 Sao Paulo Grand Prix. ----------------------------------------------------------------------------------------------------------------- Follow us on our socials: https://linktr.ee/gridtalkuk Support us on Patreon: https://www.patreon.com/c/GridTalkuk Thank you to Hollie Eagle, Jared Bradley, Kevin Beavers, Bill Armstrong and David Paulsen for their Patreon support! Review The Grid Talk Podcast? Do you enjoy the Grid Talk podcast? If you do, we would love it if you could take five to leave us a 5-Star review on iTunes! And if you don't love Grid Talk, please contact us and let us know what we could do better so we can improve. #Formula1Podcast #Formula1 #F1 Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

NORRIS BEGINS NAILING THE FINAL NAILS IN THE CHAMPIONSHIP!...PIASTRI LOOSING INTEREST…MAX DRIVER OF THE DAY AND...FERNANDO READY FOR LAS VEGAS. THIS WEEK'S NASIR HAMEED CORNER, WE KEEP IT SIMPLE WITH SOME DUKE OF DIJON AND NASIR BANTER! It was a dominant performance from Lando Norris as he claimed his seventh victory of the year, following up on his victory in the sprint race with another 25 points on Sunday, extending his championship lead to 24 points over Oscar Piastri. Early race incidents would leave Oscar Piastri with a shock penalty and lead to the retirement of Charles Leclerc through no fault of his own. And in unexpected fashion, Max Verstappen would grab fans' attention following his conversion of a pit-lane start all the way to a P3 finish, grabbing a podium on a day many fans would expect his championship shot to slip away from him. None of the top ten were able to get past each other in the initial portion of Lap 1 except Liam Lawson on George Russell, with Lewis Hamilton's Ferrari having the weakest start of any on the grid, dropping four places into 17th. A loss of control from home favorite Gabriel Bortoleto in the Sauber occurred only halfway through the first lap, causing the 21-year-old to hit the barriers, bringing out a safety car and ending his race. The safety car was brought out for the third time in a row at the Brazilian Grand Prix, lasting for three laps and coming in on Lap 4. There was more chaos immediately, as Charles Leclerc, Kimi Antonelli and Oscar Piastri went three abreast at Turn 1 after the Italian struggled to keep up with Lando Norris' pace following the restart. Piastri and Antonelli would collide, sending the Mercedes into Leclerc's Ferrari and causing the Monegasque racer to lose both a tire and incur suspension damage, ending his race prematurely. Unable to continue, Leclerc's Ferrari would pull over and bring out a Virtual Safety Car, with the McLarens of Norris and Piastri leading from the Mercedes of Antonelli and the Racing Bull of Isack Hadjar. Laps 14 and 17 would see ten-second penalties applied for both Yuki Tsunoda and Oscar Piastri, with Tsunoda's given for an incident with Lance Stroll and Piastri's for the aforementioned crash after the safety car restart. Verstappen, who had taken an early pit stop to change from hard tires to mediums, found himself up to seventh by Lap 19 thanks to Hadjar and Pierre Gasly entering the pit lane. Seventh turned into fifth by Lap 21, the Dutchman having gained 15 places in the first third of the race and looking impressive as he looked to restore his championship ambitions. LANDO: “It was an amazing race, and it's nice to win here in Brazil. It's an amazing track with amazing fans. This one was for one of my mentors, Gil, I hope he'd be very proud. “It was a great win, but to be honest, seeing how quick the competition was  today, it's clear we've still got work to do. I'll go back, see the team, congratulate them and see what we can do better. Looking ahead, I'll keep focusing on myself, keep my head down, ignore the noise and keep pushing.” MAX: From pitlane to podium, this weekend has completely turned around for me, something that I didn't think was possible. The start of the race was very hectic and I picked up a puncture early on from a load of debris on the track which meant that I pretty much had to start the race again. The Team used the right strategy from start to finish which allowed me to get through all of the traffic very efficiently. I definitely had to send it a few times to get past the other cars but I love doing that and ended up having an unexpectedly fun race. Overall it showed that we had really good pace today and that the grip was much better than the last couple of days. The atmosphere at Interlagos was amazing and it really spurred me on. I am so proud of the Team and would like to thank them for all of the hard work that they put into making the changes post Quali last night. SAO PAULO, BRAZIL - NOVEMBER 09: Race winner Lando Norris of Great Britain and McLaren Second placed Andrea Kimi Antonelli of Italy and Mercedes AMG Petronas F1 Team Third placed Max Verstappen of the Netherlands and Oracle Red Bull Racing and Mark Norris, Director of Commercial Trackside Operations at McLaren on the podium during the F1 Grand Prix of Brazil at Autodromo Jose Carlos Pace on November 09, 2025 in Sao Paulo, Brazil. (Photo by Mark Thompson/Getty Images) We kept pushing and took multiple risks this weekend because we never want to settle for second and we didn't give up. To start in the pitlane and finish P3 on the podium only 10 seconds off P1 was incredible. Now all we can do is keep fighting hard over the final few races of the season and do the best that we possibly can whilst trying to find as much performance as we can extract from the car. A huge congratulations to Kimi as well, he drove amazingly well which will have given his confidence a huge boost which is great for any rookie!" Alex Albon: It was a good race for the fans today but unfortunately for us it was a bit of a race to forget. We had good pace when we could show it. We've struggled with pace all weekend but seem to have recovered a little bit today. In the end what took us out of contention for points was that I think we stayed out too long on the first stint and we never really recovered from there. In the last stint we were quick and were fighting our way back up the grid and just missed out on a point at the end. It's frustrating that our rivals scored points today, but we will regroup and look forward to a better weekend in Las Vegas. Carlos Sainz: Not the day I was hoping for. Once I got squeezed on turn 1, I had considerable damage to the car and my race was compromised from there. We managed to stay in the hunt for points most of the race but after a slow first stop and compiled with the damage, that was it unfortunately. Time to go back home and see what we can do in these types of circuits, as Qatar will also be a challenge. A few races to go, so we cannot relax. Let's keep going.  

4 races to go, 3 drivers in contention. We go to Interlagos in Sao Paulo where the racing, and the rain, are always unpredictable.

Schon der Samstag brachte in Sao Paulo jede Menge Action und Spektakel. Gabriel Bortoleto sorgte mit seinem Horror-Crash unfreiwillig für den Höhepunkt. Wir haben die Daten zum schlimmsten Abflug der letzten Jahre. Und wir haben die Details zum Versuch der Sauber-Mechaniker, in kürzester Zeit ein Ersatzauto auf die Räder zu stellen. Auch das WM-Duell stand am Samstag im Fokus. Lando Norris reitet eine Welle des Erfolges. Warum hat Teamkollege Oscar Piastri so zu kämpfen? Und warum kommt Red Bull überhaupt nicht auf Touren? In unserer neuen Folge von Formel Schmidt haben wir die Antworten! #Formel1 #F1 #SaoPauloGP #Bortoleto #Crash #Sauber #LandoNorris #OscarPiastri #RedBullRacing #FormelSchmidt #Motorsport #F1Analyse

Formel 1 #2511: Stracke an der Strecke- #SaoPaulo #BrazilGP Sprint FORMEL 1 Sao Paulo Brasilien Grand Prix GP Rückblick Sprint Vorschau Grand Prix Heute gibt's die kurze Einschätzung vom Sprint mit meinem Gast, F1 Star-Fotograf Lukas Gorys – inklusive Kurzinterviews mit Lando Norris und Oscar Piastri. Bei Stracke an der Strecke seid ihr auf der Pole Position wenn es um den exklusiven Blick hinter die Kulissen der Formel 1 geht. Zur Formel 1 Saison 2025 bringt euch „Stracke an der Stecke“ News, Blicke hinter die Kulissen und lässt auch die Formel 1-Protagonisten zu Wort kommen. VIEL SPASS beim Anhören! Ich freue mich über likes und folgt mir für mehr – am besten im Abo z.B. über Itunes, Spotify, Soundcloud, RTL + und überall wo es Podcasts gibt Ciao, Eure Inga Stracke an der Strecke

Formel 1 #2511: Stracke an der Strecke- #SaoPaulo #BrazilGP Sprint FORMEL 1 Sao Paulo Brasilien Grand Prix GP Rückblick Sprint Vorschau Grand Prix Heute gibt's die kurze Einschätzung vom Sprint mit meinem Gast, F1 Star-Fotograf Lukas Gorys – inklusive Kurzinterviews mit Lando Norris und Oscar Piastri. Bei Stracke an der Strecke seid ihr auf der Pole Position wenn es um den exklusiven Blick hinter die Kulissen der Formel 1 geht. Zur Formel 1 Saison 2025 bringt euch „Stracke an der Stecke“ News, Blicke hinter die Kulissen und lässt auch die Formel 1-Protagonisten zu Wort kommen. VIEL SPASS beim Anhören! Ich freue mich über likes und folgt mir für mehr – am besten im Abo z.B. über Itunes, Spotify, Soundcloud, RTL + und überall wo es Podcasts gibt Ciao, Eure Inga Stracke an der Strecke

Schon der Samstag brachte in Sao Paulo jede Menge Action und Spektakel. Gabriel Bortoleto sorgte mit seinem Horror-Crash unfreiwillig für den Höhepunkt. Wir haben die Daten zum schlimmsten Abflug der letzten Jahre. Und wir haben die Details zum Versuch der Sauber-Mechaniker, in kürzester Zeit ein Ersatzauto auf die Räder zu stellen. Auch das WM-Duell stand am Samstag im Fokus. Lando Norris reitet eine Welle des Erfolges. Warum hat Teamkollege Oscar Piastri so zu kämpfen? Und warum kommt Red Bull überhaupt nicht auf Touren? In unserer neuen Folge von Formel Schmidt haben wir die Antworten! #Formel1 #F1 #SaoPauloGP #Bortoleto #Crash #Sauber #LandoNorris #OscarPiastri #RedBullRacing #FormelSchmidt #Motorsport #F1Analyse

Verliert Max Verstappen am Sonnabend vor dem eigentlichen Formel 1-Hauptrennen in Interlagos, einem Stadtteil von Sao Paulo, schon seine WM-Chancen? Welche technischen Zusammenhänge und Grundsätze stecken hinter der Schlappe des Niederländer im Sprint-Qualifying, und was heißt das fürs Rennen am Sonntag? PITWALK-Chef Norbert Ockenga und -Grand Prix-Reporterin Inga Stracke gehen diesen Fragen in der neuen Episode von PITCAST auf den Grund. Dazu gibt's auch noch eine spektakuläre Neuverpflichtung für die große #Speedway Talk Night am 14. November in Zeven bei Bremen, die Ockenga moderieren wird. Mehr Infos dazu und auch die letzten paar verbleibenden Karten zu kaufen findet Ihr hier: https://www.bahndienst.com/post/hammer-egon-m%C3%BCller-kommt-zur-talk-night-nach-zeven

Cursos IED com desconto exclusivo para seguidores do Buongiorno San Paolo: https://bit.ly/ied-buongiornoJunte-se ao network de Buongiorno San Paolo com o aplicativo Bizzy Now: https://go.bizzynow.com/buongiornosanpaolo2025 "Fundir Arte e Vida" era o lema de D'Annunzio. As histórias de Ludmila e Alexandre estão entrelaçadas na vida e no design.A família Lepri deixou a pequena ilha de Elba, na Toscana, e chegou ao Brasil, trazendo consigo a tradição de trabalho, os materiais e a qualidade do artesanato italiano. Aqui, geração após geração, esse legado foi transmitido, e ao longo dos anos, projetos como a Casa Lepri e colaborações como a com Alexandre Salles, arquiteto e designer de interiores de renome internacional que mescla autenticidade, humanidade e acessibilidade em sua arte.Falamos sobre isso no Podcast Show sobre Design, realizado em colaboração com o IED Brasil.Nosso podcast, L'ITALIA è QUI, 2ª edição, comemora 20 anos do IED no Brasil.Agradecimentos especiais a: IED São Paulo Aignep - Grupo Bugatti Libet Iter Bizzy Now Costa CruzeirosQuer participar do Podcast, realizar um evento corporativo, propor uma parceria ou apenas trocar uma ideia? A Buongiorno San Paolo é feita de encontros e estamos prontos para o próximo !Preencha o formulário ou entre em contato pelos nossos canais. Vamos adorar saber como podemos colaborar: https://buongiornosanpaolo.com.br/ 

The championship heads to where it always feel like an inflection point...It can be wet, it can be wild, and there's a sprint to add to the drama, its the Sao Paulo GP! Andy and Cody are back on the mics and they will look at all of the recent news, analyze the track facts and then take a stab at what they think will happen during the weekend with the predictions game! Chat with Cody & Andy on Twitter, BlueSky, Instagram, Reddit, and Discord @outlapf1podcast. E-mail us at outlapf1@gmail.com. Donate to the podcast here at https://anchor.fm/outlapf1/support.

Oliver Welter über Naked Lunch und Neuanfänge“Lights and a slight taste of death” ist der nicht gerade kryptische Titel des ersten Naked Lunch Albums seit 12 Jahren. Oliver Welter besuchte uns dazu, und wir sprachen mit ihm darüber, warum dieses Album gerade jetzt das Licht der Welt erblickt hat, welche Krisen und Neuanfänge es brauchte, und warum man sich im kreativen Schaffen nicht zu sehr von Erwartungshaltungen leiten lassen sollte. Bei einer Bandgeschichte von über 35 Jahren, vor allem einer, die kurz davor war weltberühmt zu werden, darf aber auch ein gewisses “Best Of” nicht fehlen, so erzählt uns Oliver auch ein paar Anekdoten aus vergangenen Tagen: von einem Videodreh in Sao Paulo bis zu ihrem “Superstardom-Klischee-Moment” in New York. Herausgekommen ist dabei ein wunderbar aufrichtiges Gespräch mit einem der wohl wichtigsten Musiker Österreichs der letzten 30 Jahre. Bon Appetit.

Betty and Christian are joined by the BBC's Jennie Gow to preview the Brazilian GP. What does Lando need to do now he's leading from the front? How can Oscar turn his form around? Is Max still in it? And is every Brit in F1 biased towards Lando? Plus we'll talk about rumours linking Ollie Bearman with Ferrari, including Jennie's thoughts on how long Lewis will stay at Ferrari for. We tell you everything you need to know about Interlargos and Chris McCarthy from F2 commentary fame joins us to talk about Purple Sectors, a brilliant sim-racing extravaganza in aid of Young Epilepsy.EXCLUSIVE NordVPN Deal ➼ https://nordvpn.com/tfatc Try it risk-free now with a 30-day money-back guarantee!And want to know more about Purple Sectors? You can get tickets, join in the fun and support the cause here… https://www.youngepilepsy.org.uk/join-setting-purple-sectors-sim-racing-fundraiser Hosted on Acast. See acast.com/privacy for more information.

Only four races remain and a single point separates the top 2. It's going down to the wire as we head into our penultimate sprint race weekend around the legendary Autódromo José Carlos Pace in Sao Paulo. Louis Edwards is joined by Owain Medford and Tom Horrox to speculate on what could be another twist in this exciting Formula One season. ----------------------------------------------------------------------------------------------------------------- Follow us on our socials: https://linktr.ee/gridtalkuk Support us on Patreon: https://www.patreon.com/c/GridTalkuk Thank you to Hollie Eagle, Jared Bradley, Kevin Beavers, Bill Armstrong and David Paulsen for their Patreon support! Review The Grid Talk Podcast? Do you enjoy the Grid Talk podcast? If you do, we would love it if you could take five to leave us a 5-Star review on iTunes! And if you don't love Grid Talk, please contact us and let us know what we could do better so we can improve. #Formula1Podcast #Formula1 #F1 Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

The carnival of chaos is BACK! The Sao Paulo Grand Prix never disappoints — wild weather, insane overtakes, and a track that always delivers drama. This year, the championship fight is tighter than ever: Lando Norris leads by just ONE point, Oscar Piastri's hanging on, and Max Verstappen's charging back — only 35 points behind. With a Sprint weekend on deck, there are extra points and extra pressure. Will Lando hold the line? Can Oscar keep his championship hopes alive? Or is Max about to unleash full send mode and blow this title fight wide open? Grab your caipirinhas and strap in — this is going to get spicy.

How do you determine what makes a great city? This week on Unpacked, Afar editor at large Laura Dannen Redman sits down with Chris Fair, president and CEO of Resonance Consultancy, to unpack the firm's annual World's Best Cities ranking. Chris explains how the list measures livability, lovability, and prosperity; the UK city that still tops the chart; the methodology changes that reshaped the top 100; and what the ranking means for overtourism, climate risk, and destination marketing. In this episode you'll learn How Resonance measures a city's livability, lovability, and prosperity The two cities that remain neck and neck at the top of the list Which cities climbed or slipped after switching data sources from TripAdvisor to Google Maps The perception gap between measured performance and global awareness, with Sao Paulo as a case study How climate risk and resilience are starting to factor into city rankings Don't miss these moments [00:03:00] How the ranking began as a consulting tool and evolved into a public benchmark [00:08:00] The top 10 cities, revealed [00:10:00] Why switching from TripAdvisor to Google Maps changed the makeup of the top 100 [00:11:00] Sao Paulo's rise in lovability and the perception gap in Ipsos survey results [00:16:00] The emerging role of climate risk and resilience in city rankings [00:20:00] The challenge of destination concentration and how only a handful of places capture most traveler interest [00:23:00] Vancouver's spot at 41 and what it reveals about livability versus prosperity Meet this episode's guests Laura Dannen Redman, Afar editor at large Chris Fair, president and CEO, Resonance Consultancy Resources Read the full World's Best Cities report at WorldsBestCities.comExplore Afar's coverage of the World's Best Cities List Read about the WrldCity Forum, hosted by Resonance If you're interested in small city rankings or regional lists, check Resonance's Americas and Europe city reports Stay Connected Sign up for our podcast newsletter, ⁠⁠⁠⁠⁠⁠⁠⁠Behind the Mic⁠⁠⁠, where we share upcoming news and behind-the-scenes details of each episode.  Explore our other podcasts, View From Afar, about the people and companies shaping the future of travel, and ⁠Travel Tales⁠⁠⁠, which celebrates first-person narratives about the way travel changes us. Unpacked by Afar is part of ⁠⁠⁠Airwave Media⁠⁠⁠'s podcast network. Please contact ⁠⁠⁠advertising@airwavemedia.com⁠⁠⁠ if you would like to advertise on our podcast. Learn more about your ad choices. Visit megaphone.fm/adchoices

Avant la conférence des Nations unies sur le climat qui commence la semaine prochaine, le Brésil accueille les 6 et 7 novembre 2025 le sommet des dirigeants. Le président Lula a fait le choix symbolique de réunir les participants à Belém, au cœur de l'Amazonie. Après les COP en pays pétrolier, à Dubaï et à Bakou, place à un hôte champion des énergies renouvelables, qui veut protéger les forêts et qui a une société civile vivante. Mais le Brésil est aussi le 6ème producteur mondial de pétrole, la mère patrie de l'agrobusiness et le deuxième exportateur mondial de viande de bœuf. Avec nos invités :  - Hervé Théry, géographe, directeur de recherche émérite au CNRS et professeur à l'Université de Sao Paulo au Brésil. Auteur de Amazone - Un monde en partage, CNRS éditions  - Catherine Aubertin, économiste de l'environnement et directrice de recherche à l'Institut de recherche pour le développement (IRD), affectée au Muséum national d'Histoire naturelle, autrice de « La nature en partage », IRD Éditions.

Only four races remain and a single point separates the top 2. It's going down to the wire as we head into our penultimate sprint race weekend around the legendary Autódromo José Carlos Pace in Sao Paulo. Louis Edwards is joined by Owain Medford and Tom Horrox to speculate on what could be another twist in this exciting Formula One season. ----------------------------------------------------------------------------------------------------------------- Follow us on our socials: https://linktr.ee/gridtalkuk Support us on Patreon: https://www.patreon.com/c/GridTalkuk Thank you to Hollie Eagle, Jared Bradley, Kevin Beavers, Bill Armstrong and David Paulsen for their Patreon support! Review The Grid Talk Podcast? Do you enjoy the Grid Talk podcast? If you do, we would love it if you could take five to leave us a 5-Star review on iTunes! And if you don't love Grid Talk, please contact us and let us know what we could do better so we can improve. #Formula1Podcast #Formula1 #F1 Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Who is the most languid driver in Formula 1? And will Felipe Massa win his case of the century in the latest episode of Sao Paulo Justice?Formula McGinley

Timo & Mattey sind aus dem Urlaub zurück und widmen sich in dieser Folge natürlich dem Kampf um die Fahrer-Weltmeisterschaft, den Gerüchten um das Interesse an Rookie Ollie Bearman von Ferrari und die möglichen Konstellationen bei Red Bull Racing und Racing Bulls für 2026. Viel Spaß!

F1TV commentator and former Renault driver Jolyon Palmer, and De Telegraaf journalist Erik van Haren, join Tom Clarkson to preview this weekend's Sao Paulo Grand Prix. With four races and two F1 Sprints to go, Lando Norris leads Oscar Piastri at the top of the World Championship by just one point. How has Lando turned around a 34-point deficit to Oscar since his DNF in Zandvoort? Will the pressure change now he's gone from ‘hunter' to ‘hunted'? And having not been on the podium in the last four races, can Oscar regain momentum? In Mexico, Max Verstappen gained more ground in his late push to win a fifth championship in a row. Now 36 points off the lead, are Max's title chances in his own hands? And if he was to complete an incredible comeback, where would that achievement rank among his other successes? Erik also shares insight into Red Bull's transformation under Team Principal Laurent Mekies and what Max's future may hold after 2026. Plus, the guys discuss how the incredibly tight battle between Ferrari, Mercedes and Red Bull for P2 in the Constructors' Championship could play out. Listen to more official F1 podcasts In-depth interviews with F1's biggest stars on F1 Beyond The Grid Your F1 questions answered by the experts on F1 Explains Experience the 2025 F1 title fight Book your seat for a Grand Prix this season at tickets.formula1.com

+Veličanstveno finale sezone se nastavlja u Brazilu - sprint vikendom!+Samo 36 poena deli vodeću trojicu.+Ko će biti trn u oku vodećima - Mercedes ili Ferrari?GENERALI I LAP 76 POKLANJAJU BESPLATAM VAUČER ZA PREGLED PROSATE

33 points up for grabs in Brazil as the 2025 Formula 1 season enters the final 4 races of the season. The Sao Paulo GP will host a Sprint and Grand Prix this weekend, and there are two reasons why Max Verstappen will score MAX in Brazil at the legendary Interlagos. Only one of them is numerology! Will Mercedes be in the mix to give Verstappen a points cushion against the McLaren drivers Lando Norris and Oscar Piastri? And what about Yuki Tsunoda, who is fighting to keep his place in Red Bull Racing. We love Interlagos, and it seems as though the F1 Sprint format is tailor-made for this historic circuit. Gabriel Bortoleto is the future of Brazil in Formula 1 and while Oliver Bearman is being talked up as the next Ferrari driver, we suspect even Bortoleto might have an outside chance!The battle for P2 in the Constructors' Championship hots up, as does the battle for P6. Lots to race for...and fight for in Sao Paulo this weekend. Join Soumil, Sundaram and Kunal on the livestream to discuss the 2025 Sao Paulo Grand Prix. Send us your thoughts and predictions in the comments! #F1 #F12025 #BrazilGP #SaoPauloGP Learn more about your ad choices. Visit megaphone.fm/adchoices

Liam Lawson says his future in Formula One remains unclear and he expects performance over the final five race weekends to decide his fate. In an exclusive interview with the Mike Hosking Breakfast, the Racing Bulls driver talked about the pressures of Formula One, his demotion from the Red Bull team and what needs to be done to secure a seat for the 2026 season. The Kiwi is in a battle for a seat alongside Red Bull driver Yuki Tsunoda, teammate Isack Hadjar and Red Bull junior Arvid Lindblad. Only four-time world champion Max Verstappen is confirmed at Red Bull next year, signed through to 2028. He is expected to be partnered by Hadjar, who is the next best driver on the organisation's books so far in his rookie season. And with Red Bull understood to be eager to promote 18-year-old Lindblad after one season of Formula Two, Lawson and Tsunoda have effectively been left in a shootout for that final place to partner the junior at Racing Bulls. Lawson heads into this weekend's racing in Brazil, which includes a sprint race, on 30 points and 15th place on the driver standings, two points and places ahead of Tsunoda. He told Mike Hosking that his future in the sport remains unknown and he just has to keep performing on the track. “At this point right now, the decision is not clear and hasn't been made and has us in a position where basically I'm still working towards trying to secure that seat,” he said. “I think the pathway or the guide is to perform. And if you perform, you stay in the sport. That's just how it's been since I was 16 years old. That's how it's been since I joined the programme. That's just how it is. And that's basically my guide,” Lawson said. “It's at the point of the year where obviously the decisions are being made around the four seats that are in our camp for next year. It's something that obviously I'm very aware of. But at the same time, it doesn't change really anything I'm doing. It doesn't change the approach to each race weekend. All that stays the same,” he added. “I think all of the hard stuff makes you better anyway,” he reflected on the season. “And if I come out of this year, which is what I'm trying to do, I'll be in a much better place because of sort of the hard stuff that's been on this year.” Lawson is readying for this week's Brazilian Grand Prix after a disappointing outing in Mexico, where his race lasted only a few laps and he was lucky to avoid two marshals who ran across the track. Last year he finished ninth in both the sprint and Grand Prix races in Sao Paulo, with an impressive fifth placing in qualifying for the main race. This year's season culminates with race weekends in Las Vegas, Qatar and Abu Dhabi, after which Red Bull will make their decision on the 2026 drivers. Lawson started the season in the Red Bull car with defending world champion Verstappen as his teammate but was demoted to the Racing Bulls team just two races into the season. His replacement Tsunoda has also struggled in the car and sits behind the Kiwi on the points standings. Lawson said he reflects more about his lack of time in the Red Bull car than how the Japanese driver has performed since replacing him. “It's not something I think about directly with him. I think that, at the end of the day, I had two races on two tracks I'd never been to. We didn't do pre-season, we didn't do a load of testing last year and pre-season testing to get it ready for this season. So, I would never be able to compare because I just didn't do the races. I did two and then I was out. He's had the whole season in the car. “I could never compare because, obviously, as a racing driver, we always back ourselves, right? And I'm always going to sit here and go, ‘hey, after the amount of time, I feel like I would have got my head around it and been somewhere'. But I think, to compare … we didn't get given the same amount of races." Hosking also asked Lawson how he would score himself this season, to which he responded: “Not high enough, not as high as I wanted to.” “I think it's very rare to look back on stuff and think I did everything exactly as I wanted to do. For me, as long as I look back on this year and learn from things that I feel like I could have done better. I think we've done a really good job through a good part of this year. The second half of the year has been a lot stronger. I think we were trying to play catch-up for the first part, because of the way the start of the year unfolded. “And I think that we definitely got there, but in a sport where there's just so many variables and you don't put one piece of the puzzle together on a race weekend and, especially in a season that's so close, you just get knocked out and you're fighting where you don't want to be fighting. I think that trying to do that every single weekend and have everything go right is very tough, but those are the things that I look back on and learn from.” The 23-year-old said a key lesson has been the pace of the Formula One season off the track. “It's crazy how you leave a race weekend and just straight away switch on to the next one. I think that's been something that has been a learning process this year … the things that I can learn from and just straight away move on to the next one, you don't really have time to dwell or think about what's happened.” LISTEN ABOVE See omnystudio.com/listener for privacy information.

Los futuros de los índices de Wall Street subían, lo que sugiere que el repunte de las acciones impulsado por la tecnología aún tiene margen para continuar; Lula y Sheinbaum hablan de libre comercio; Milei cambia gabinete tras victoria en legislativas; Dayanne Sousa, periodista de Bloomberg News en Sao Paulo, habla como las ganaderas en Brasil quieren mejorar su imagen antes de la COP30.Newsletter Cinco cosas: bloom.bg/42Gu4pGLinkedin: https://www.linkedin.com/company/bloomberg-en-espanol/Youtube: https://www.youtube.com/BloombergEspanolWhatsApp: https://whatsapp.com/channel/0029VaFVFoWKAwEg9Fdhml1lTikTok: https://www.tiktok.com/@bloombergenespanolX: https://twitter.com/BBGenEspanolProducción: Eduardo ThomsonSee omnystudio.com/listener for privacy information.

Continúan los megaoperativos en Brasil para combatir el crimen organizado. Este jueves fue en Sao Paulo contra el lavado de dinero del “Primeiro Comando da Capital”, la mafia más grande del país. Las cifras del operativo, que terminó con cuatro personas detenidas y otra murió, no se comparan con las del pasado martes en Río de Janeiro que dejó cerca de 121 fallecidos. El objetivo es el mismo, combatir el crimen organizado, pero el método de las autoridades brasileñas cambia según el lugar: mientras más pobre es la zona la policía interviene con más violencia, alerta Paulo Cesar Carbonari, miembro del Movimiento Nacional de Derechos Humanos de Brasil. Para él, el operativo en Rio de Janeiro del martes y el del jueves en la ciudad de Campinas, Estado de Sao Paulo, son una clara muestra de esta desigualdad.   “En los dos casos son muy, muy ilustrativos y muy importantes, porque en San Paulo es una operación que se hizo en una región donde no están los pobres, donde están los más ricos del país. En Río la operación de estos días fue en dos de las mayores favelas de la ciudad, donde están millones de personas trabajadoras, pobres, mujeres, jóvenes, sobre todo negras y negros. La situación es muy clara, o sea, no se combate el crimen organizado atacando las poblaciones, las favelas, porque ahí no están los que manejan el dinero del crimen organizado. Por eso cuando ocurre lo que ocurrió en Río de Janeiro, no están combatiendo el crimen organizado, están combatiendo a la población”, se interroga Carbonari. El balance oficial del operativo en Río de Janeiro es de 121 muertos y 113 detenidos, lo que la convirtió en la operación más mortal de la historia de Brasil. Las familias acudieron a reconocer los cuerpos acomodados a lo largo de una calle. Carbonari alerta que operaciones como la de Río de Janeiro no debería existir. “Hay una decisión del Tribunal Superior Constitucional de Brasil para que se hagan operaciones en las favelas. El Gobierno de Río no respetó ni las reglas elementales, ni la decisión judicial del Tribunal Superior sobre lo que debía hacer, por lo tanto, exigir una investigación justa es necesario para que no se quede en impunidad, agregó”. El operativo de Campinas buscaba cumplir nueve órdenes de detención y once de allanamientos. Uno de los cuatro detenidos era un influencer llamado Eduardo Magrini, que presume un Rolex, regalo de un artista, y que la Fiscalía lo identifica como un miembro importante del Primeiro Comando da Capital. “No es que la policía de Sao Paulo sea mejor que la de Río de Janeiro”, indica Carboneri, quien asegura que las autoridades entran de forma más violenta en comunidades vulnerables, “pero no tan violenta, o sea con otras formas y otras estrategias en -lugares- donde no están los pobres”, aseveró. Cesar Carbonari resaltó que en Brasil falta una estrategia nacional contra el crimen organizado porque son los gobiernos locales los que ordenan los operativos como los dos de esta semana.

Continúan los megaoperativos en Brasil para combatir el crimen organizado. Este jueves fue en Sao Paulo contra el lavado de dinero del “Primeiro Comando da Capital”, la mafia más grande del país. Las cifras del operativo, que terminó con cuatro personas detenidas y otra murió, no se comparan con las del pasado martes en Río de Janeiro que dejó cerca de 121 fallecidos. El objetivo es el mismo, combatir el crimen organizado, pero el método de las autoridades brasileñas cambia según el lugar: mientras más pobre es la zona la policía interviene con más violencia, alerta Paulo Cesar Carbonari, miembro del Movimiento Nacional de Derechos Humanos de Brasil. Para él, el operativo en Rio de Janeiro del martes y el del jueves en la ciudad de Campinas, Estado de Sao Paulo, son una clara muestra de esta desigualdad.   “En los dos casos son muy, muy ilustrativos y muy importantes, porque en San Paulo es una operación que se hizo en una región donde no están los pobres, donde están los más ricos del país. En Río la operación de estos días fue en dos de las mayores favelas de la ciudad, donde están millones de personas trabajadoras, pobres, mujeres, jóvenes, sobre todo negras y negros. La situación es muy clara, o sea, no se combate el crimen organizado atacando las poblaciones, las favelas, porque ahí no están los que manejan el dinero del crimen organizado. Por eso cuando ocurre lo que ocurrió en Río de Janeiro, no están combatiendo el crimen organizado, están combatiendo a la población”, se interroga Carbonari. El balance oficial del operativo en Río de Janeiro es de 121 muertos y 113 detenidos, lo que la convirtió en la operación más mortal de la historia de Brasil. Las familias acudieron a reconocer los cuerpos acomodados a lo largo de una calle. Carbonari alerta que operaciones como la de Río de Janeiro no debería existir. “Hay una decisión del Tribunal Superior Constitucional de Brasil para que se hagan operaciones en las favelas. El Gobierno de Río no respetó ni las reglas elementales, ni la decisión judicial del Tribunal Superior sobre lo que debía hacer, por lo tanto, exigir una investigación justa es necesario para que no se quede en impunidad, agregó”. El operativo de Campinas buscaba cumplir nueve órdenes de detención y once de allanamientos. Uno de los cuatro detenidos era un influencer llamado Eduardo Magrini, que presume un Rolex, regalo de un artista, y que la Fiscalía lo identifica como un miembro importante del Primeiro Comando da Capital. “No es que la policía de Sao Paulo sea mejor que la de Río de Janeiro”, indica Carboneri, quien asegura que las autoridades entran de forma más violenta en comunidades vulnerables, “pero no tan violenta, o sea con otras formas y otras estrategias en -lugares- donde no están los pobres”, aseveró. Cesar Carbonari resaltó que en Brasil falta una estrategia nacional contra el crimen organizado porque son los gobiernos locales los que ordenan los operativos como los dos de esta semana.

Les habitants du nord des Caraïbes se réveillent dans les décombres du passage de l'ouragan Melissa. Le nombre de victimes ne cesse d'augmenter. L'ouragan Melissa se dirige désormais vers les Bermudes qu'il devrait atteindre ce soir (30 octobre 2025). L'ouragan a déjà dévasté plusieurs îles des Caraïbes. Haïti paye le plus lourd tribut. En Haïti, le dernier bilan est de 24 morts, 18 disparus et de nombreux blessés, rapporte Le Nouvelliste. Le bilan peut encore évoluer, affirme Frantz Duval, rédacteur en chef du Nouvelliste sur notre antenne. «Le gouvernement semble pris de court, affirme-t-il. On n'a pas encore annoncé de mesures concrètes. Ils sont comme le reste de la population, ils ne savent pas vraiment ce qu'il s'est passé dans les villes de province».   Cuba, entre ouragan et blocus Cuba est donc le dernier pays touché par Melissa. Les inondations sont le principal problème pour l'île, estime le site 14 y medio. Des torrents d'eau emportant tout sur leur passage. Les pluies abondantes ont continué même après le passage de Melissa. Le fournisseur d'électricité national a annoncé qu'une grande partie de la population se trouvait sans électricité, mais aussi sans réseau téléphonique. Le pays traverse une grave crise économique et certains habitants des zones sinistrées se sentent abandonnés. «Avant l'arrivée de l'ouragan, les autorités sont venues nous dire de trouver nous-mêmes un endroit où nous mettre à l'abri parce que le gouvernement n'avait pas de lieux où nous évacuer», témoigne Elsa Listy Isacc Reyes jointe par RFI. Cette mère d'un adolescent de 17 ans vit à 40 km de Santiago de Cuba. Sa maison a été détruite. «Moi, je suis allée me réfugier chez ma voisine, ajoute-t-elle. Je n'ai pas reçu d'aide pour l'instant : ni du gouvernement, ni de personne. Je n'ai pas de proches vers qui me tourner. Ma famille et moi, on est vraiment, vraiment désespérés.»   Au Brésil, la polémique grandit après l'opération policière à Rio Au Brésil, la population et les autorités tentent encore de comprendre ce qui a transformé une intervention policière contre le crime organisé en bain de sang mardi (28 octobre 2025) dans des favelas de Rio. Le bilan provisoire officiel est de 119 morts dont quatre policiers. C'est l'opération policière la plus meurtrière de l'histoire dans le pays. Pour l'heure, l'identité des morts n'a toujours pas été révélée, mise à part celle de policiers. On ne sait donc pas s'ils étaient visés par le mandat judiciaire de cette opération. Certains habitants dénoncent des exécutions et un juge de la Cour suprême brésilienne a convoqué une audience lundi prochain (3 novembre 2025) pour que le gouverneur de l'État de Rio, Claudio Castro, commanditaire de l'opération fournisse des détails. Mais dans la presse, le débat a déjà commencé. Dans un éditorial de la Folha de Sao Paulo, le journaliste Vinicius Torres Freire accuse la droite d'avoir simplement voulu relancer sa campagne par le sang. Claudio Castro est, en effet, un allié de l'ancien président Bolsonaro. «La droite était acculée, sur la défensive», développe l'éditorialiste. «Les gouverneurs de droite «expriment aujourd'hui leur solidarité» à Claudio Castro — ils tentent de diffuser l'idée que Castro et la sécurité de Rio sont abandonnés par le pouvoir fédéral, par le président Lula notamment.» La Folha précise également que «la gauche n'a jamais été capable de présenter un plan de sécurité, laissant le champ libre à une nouvelle invasion barbare des démagogues de la mort.» Le média O Globo, de son côté, a interviewé l'ancien secrétaire national de la Sécurité publique. Ricardo Balestreri reconnait que le crime organisé exerce «un pouvoir tyrannique sur une large partie du territoire de Rio» mais «aucun criminel important n'habite dans une favela», affirme-t-il. Autrement dit, combattre le crime organisé uniquement dans les quartiers les plus pauvres revient à tromper la population.   Chili : Jeannette Jara, candidate de la gauche à la présidentielle Dans deux semaines (dimanche 16 novembre), le Chili se rendra aux urnes pour le premier tour d'une élection présidentielle très polarisée. Les deux candidats qui sont, pour le moment, en tête dans les sondages sont à l'opposé l'un de l'autre. D'un côté, José Antonio Kast à l'extrême droite, face à lui Jeannette Jara, communiste et candidate de la gauche réunie. Il ne leur reste plus que quelques jours pour faire campagne et tenter d'élargir leur base électorale. Jeannette Jara qui a créé un certain engouement surtout chez les femmes. Elle qui est issue d'une famille pauvre et a gravi les échelons un à un, jusqu'à devenir ministre du Travail dans l'actuel gouvernement du président Gabriel Boric. Écoutez le reportage de notre correspondante Naïla Derroisné à Santiago.

Professeur de Sciences politiques à l'Université américaine de Paris, Philip Golub analyse pour RFI la politique étrangère de Donald Trump, qui poursuit cette semaine sa tournée en Asie. «America first», l'expression est née dans les années 1920 aux États-Unis, dans la bouche de ceux qui étaient en désaccord avec les engagements internationaux du président de l'époque, puis remise au goût du jour par Donald Trump près d'un siècle après. Il la martèle depuis son retour à la Maison Blanche. Pourtant, Donald Trump est présent sur un maximum de fronts ces derniers mois. Alors comment qualifier la politique étrangère de Donald Trump ?  «Les États-Unis sont structurellement une puissance globalisée, nuance Philip Golub. Donald Trump n'est pas un isolationniste, mais un unilatéraliste, qui veut imposer sa volonté dans différents théâtres du monde, selon ce qu'il estime être l'intérêt national des États-Unis, poursuit celui qui enseigne à l'Université américaine de Paris (AUP). Ce qui correspond d'assez près à son intérêt personnel». Il va plus loin : «La politique internationale de Donald Trump est dirigée par son ego».    Après la Jamaïque, l'ouragan Melissa touche Cuba et fait au moins 10 morts en Haïti Le jour d'après en Jamaïque. L'ouragan Melissa a traversé l'île des Caraïbes, mardi 28 octobre 2025, laissant de lourds dégâts sur son passage. Un «Désastre !» pour The Jamaica Observer. En Une du journal, s'affiche un amas de tôles et de poutres en partie immergées dans une eau boueuse. The Gleaner, pour sa part, multiplie les adjectifs choc : «Défiguré(e)», écrit le journal en majuscules, à sa Une ce mercredi 29 octobre 2025. «Ravagé(e)», lit-on aussi en titre d'un article sur son site. Le quotidien décrit les arbres arrachés, les lignes téléphoniques à terre.  Melissa a atteint, mercredi 29 octobre 2025, le sud-est de Cuba. Rétrogradé en catégorie 3 (sur 5), mais avec des vents qui peuvent encore souffler à près de 200 km/h. L'ouragan a déjà provoqué «d'importants dégâts», assure le président cubain Miguel Diaz Canel. Plus de 700 000 personnes ont été évacuées.  Haïti, pour sa part, n'a pas été touchée directement par l'œil de l'ouragan, mais toute la moitié sud du pays est en alerte rouge, y compris la capitale, Port-au-Prince. Face à cela, les autorités haïtiennes ont déclaré, ce mercredi chômé, explique Gazette Haïti. Objectif : «permettre à la population de se préparer et de réduire les risques liés au passage de l'ouragan», poursuit le site d'information.   À lire aussiLa Jamaïque, «zone sinistrée» après le passage de l'ouragan Melissa Brésil : L'opération de police la plus meurtrière de l'histoire de Rio À Rio de Janeiro, une gigantesque opération de police ordonnée par le gouverneur Claudio Castro s'est soldée, mardi 28 octobre 2025, par au moins 132 morts. Ce mercredi matin, des dizaines cadavres ont été alignés dans la rue par les habitants eux-mêmes, dans l'un des quartiers visés par l'opération, écrit Folha de Sao Paulo sur son site. Les familles cherchent à identifier les victimes. D'après les autorités, les policiers visaient des membres du principal groupe criminel de la ville, le Comando Vermelho. À lire aussiScène de guerre à Rio de Janeiro: des dizaines de morts dans une opération anti-drogue

É um dos jovens cantores e compositores brasileiros mais estimados dos últimos anos, tanto a solo na banda O Terno. A poucas semanas dos concertos com orquestra em Portugal, Tim Bernardes vem Posto Emissor falar da colaboração com o maestro Martim Sousa Tavares e também da infância marcada pela descoberta de música muito diferente, bem como da admiração por artistas portugueses – já colaborou com Salvador Sobral e Capitão FaustoSee omnystudio.com/listener for privacy information.

In this inspiring episode of the PRovoke Media podcast, Maja Pawinska Sims talks to our Young Changemakers for 2025. The four amazing young women from underrepresented backgrounds around the world have been recognised as future leaders of the communications industry, in the fourth year of the competition: Liyana Shirin in London, Elsie Merhi in Dubai, Kayla Marrero in Washington DC and Lívia Gammardella in Sao Paulo, Brazil. Before the conversation with the Young Changemakers, we speak to the woman behind the initiative, We. Communications founder and global CEO Melissa Waggener Zorkin. 

Making progress on the energy transition, net zero sustainability, and inclusive growth requires an effort that transcends borders and means involving a wide range of parties including asset owners and policymakers. Jane Ambachtsheer, Global Head of Sustainability, talks to Daniel Morris, Chief Market Strategist, about the significance of this meeting, the PRI advocacy network and its principles for responsible investment, and what investors can expect from the PRI in Person in Sao Paulo, Brazil on 4 - 6 November 2025.For more insights, visit Viewpoint: https://viewpoint.bnpparibas-am.com/Download the Viewpoint app: https://onelink.to/tpxq34Follow us on LinkedIn: https://bnpp.lk/amHosted by Ausha. See ausha.co/privacy-policy for more information.

In this heartfelt and expansive episode of The Circle of Hope podcast, I sit down with my dear friend of over thirteen years, Felipe Ferreira. Our friendship began when our professional paths crossed in the hospitality industry—Felipe based in Sao Paulo and me in Texas. Over the years, despite having only met twice in person, we've grown an immensely supportive, curious, and genuinely reciprocal relationship spanning continents, time zones, and languages.Together, we explore what makes relationships thrive across cultures and professions. Felipe shares stories of his transitions—from bustling Sao Paulo to nature-loving Rio de Janeiro, and now to his new home in Germany. He opens up about the quirks and challenges of building community in different countries, the importance of “connection agents,” and how curiosity and intentionality shape lasting circles of influence. Throughout our conversation, we reflect on how to discern which relationships to nurture, how culture and language influence connection, and the power of being both a giver and a receiver in any relationship. Whether you're moving cities, countries, or just seeking deeper connections in your everyday life, Felipe's wisdom and our shared journey highlight the joy and impact of building your own circle of hope.Watch This If:You're moving to a new city or country and want tips on building authentic connectionsYou value cross-cultural friendships and work relationshipsYou're curious about maintaining strong, long-distance friendshipsYou want to know how to be more intentional with your social circleYou enjoy personal growth stories rooted in real-life experienceYou're navigating new work environments and looking for connection strategiesQuotes to Remember:“I think it's all about the exchange—so I receive a lot, I get a lot, but maybe I can give you a little bit as well.” – Felipe Ferreira“Don't ever take for granted that the people in your circle who are most beneficial… may not be your peers.” – Valerie Hope“A smile really opens doors. And even if you cannot communicate, people can really tell if your intentions are good.” – Felipe Ferreira“Letting people go is okay. There are some people that will come and go, and that's okay.” – Felipe FerreiraWhat You'll Learn:How to leverage curiosity to build strong, authentic cross-cultural friendshipsWhy professional connections can become deep sources of personal and emotional supportPractical ways to adapt your social life after relocating to a new city or countryThe importance of “connection agents” and how they help integrate you into new communitiesHow to discern which relationships deserve your time and energyStrategies for staying connected with friends and colleagues around the globeWhy being intentional about giving and receiving is key to thriving relationshipsLet's Stay Connected:Guest: Felipe FerreiraInstagram: https://www.instagram.com/felipeofLinkedIn: https://www.linkedin.com/in/felipeof/Facebook: https://www.facebook.com/felipeoferreiraHost: Valerie HopeWebsite:https://www.valeriehope.comInstagram:https://www.instagram.com/valeriehope/LinkedIn:https://www.linkedin.com/in/valeriehope/Facebook:https://www.facebook.com/ValerieVHopeYoutube:https://www.youtube.com/@ConnecttoJoyProduction Support: Lucy Hope - Podcast Editing, Copy, and Publishing.#CircleOfHope #CrossCulturalConnections #CircleOfInfluencers #FriendshipGoals #PersonalGrowth

Ahead of COP30, Brazil is positioning itself as a leader of the climate agenda, while moving ahead with increasing ambitions in oil exploration. Can the host of the UN's convention against global warming strike a balance? Join the talk between Camila Fontana, deputy bureau chief of the Argus office in Sao Paulo, and Brazil news editor Lucas Parolin, who will be covering the COP30 in Belem in November.

來抱怨一下巴西輸台灣的地方↓↓↓ (03:10) 抱怨時間 (10:40) 新賽季會爆發的球員 (21:50) 推歌時間～ ABRILA - Muy Mala、Key Glock - She Ready 別忘了小額贊助

Sarah Aswegan, a seasoned biopharma leader and strategic advisor for global rare disease solutions, shares her journey from sales in pharma to her consulting work today. She discusses her experience in transitioning biopharma companies from clinical to commercial success, the evolution of medtech in diagnosing and managing rare diseases, and the collaborative efforts required to bring innovative treatments to market. She also shares insights on current trends in gene therapy, the dynamics of funding, and the importance of data in advancing care for rare disease patients. Guest links: www.saraaswegan.com  Charity supported:  Interested in being a guest on the show or have feedback to share? Email us at theleadingdifference@velentium.com.  PRODUCTION CREDITS Host & Editor: Lindsey Dinneen Producer: Velentium Medical   EPISODE TRANSCRIPT Episode 065 - Sara Aswegan [00:00:00] Lindsey Dinneen: Hi, I'm Lindsey and I'm talking with MedTech industry leaders on how they change lives for a better world. [00:00:09] Diane Bouis: The inventions and technologies are fascinating and so are the people who work with them. [00:00:15] Frank Jaskulke: There was a period of time where I realized, fundamentally, my job was to go hang out with really smart people that are saving lives and then do work that would help them save more lives. [00:00:28] Diane Bouis: I got into the business to save lives and it is incredibly motivating to work with people who are in that same business, saving or improving lives. [00:00:38] Duane Mancini: What better industry than where I get to wake up every day and just save people's lives. [00:00:42] Lindsey Dinneen: These are extraordinary people doing extraordinary work, and this is The Leading Difference. Hello and welcome back to another episode of The Leading Difference podcast. I'm your host Lindsey, and today I'm delighted to welcome to the show, Sarah Aswegan. Sarah is a seasoned biopharma leader helping organizations transition and grow from clinical to commercial success. She prides herself on the success of leading multiple global cross-functional teams and contributing to the success of the franchise areas she oversaw and served. Until recently, she's applied these experiences while serving in a consultancy capacity for many small to midsize biotechs entering or expanding in rare disease. She has also successfully helped organizations to start and scale adjacent spaces to biopharma, and most recently has been serving as a Global Head of Commercial Assets, Brands, and Care Solutions, and has led transformational change at UCP, having been part of the design and scale of the business unit for rare disease. She maintains a strong network among clinicians, access, bioethicists, and patient advocacy globally. Well, thank you so much for joining us today. I'm so excited to speak with you. [00:01:52] Sara Aswegan: Thanks, Lindsey. It's nice to be here. [00:01:54] Lindsey Dinneen: Wonderful. Well, I'd love, if you wouldn't mind, sharing a little bit about yourself and your background and what led you to medtech. [00:02:02] Sara Aswegan: Yeah, thanks Lindsey. You know, I, I started my career ages ago in the pharma side of things, and as my career has grown, so has the exposure across pharmaceuticals, into biotech and including aspects of medtech. As we look at some of the areas I've spent the last 18 years in rare disease, the medtech component is coming in largely around if we think about the diagnosis component and then the management of the different conditions over the lifespan of a child or adult affected by a rare condition. You can see things really evolving. I started my career on the sales side of things. My education is in business and communication, so anyone can learn the science if you have good mentors and people to help you along the way. And I was really, really fortunate to work amongst a team of amazing individuals, both in the US and then now having lived away for about 15 years outside of the US that have helped open my eyes to what can be possible and the differences by markets. And as I mentioned, I spent the last 18 years in the rare disease space really helping companies of all sizes build out and scale their teams, bringing in new assets and bringing solutions to the field of rare disease. And it's something I'm very passionate about. [00:03:06] Lindsey Dinneen: Yeah. Well, thank you for sharing a little bit about that. So I'm curious, that's a very specific niche and I would love to understand how you arrived at that and how you realized, "Oh, this is what I'm meant to be doing." [00:03:19] Sara Aswegan: Yeah. So I made a move geographically and company-wise to a small firm at the time. We were just a very small team. We called it the bootstrapping team at Shire Human Genetic Therapies, and I moved from the Chicago area to Boston, and that was my first really exposure to rare diseases. And, it's a completely different field and it continues to evolve even to this day. But the closeness and proximity you have to patients and their families and those with unmet need. And I have, you know, a couple of close friends as well as a family member that's been affected by a rare disease. So as you're seeking care and support for them, it's not always about the medications. It's about that total person and thinking really holistically about the individual and their care teams that are impacted by those conditions. So the external community we were serving really drove me and introduced me to something that I've stayed with, and it brings great passion to try to find ways to support individuals in our western society, but also looking at low middle income countries and helping facilitate diagnosis to treatment to, again, that whole supportive care and largely from the internal teams within the organizations I've worked with has just is been tremendously rewarding and also equally challenging. It's beautiful to see progress. I mentioned diagnosis and. One of the areas I worked in initially was in the lysosomal storage disease area. And it's the age-old question on diagnosis. Do you facilitate newborn screening, for example, so when your child is born, you have a heel prick done and you can do a series of tests depending on the state you live in, and in some countries in Europe it's also provided. But if there's not a therapy, is it okay to do that type of diagnosis support. And so that challenge, you know, in seeing the policy evolve on a state by state basis. When I began in the rare disease space and MPS Type Two Hunter Syndrome, it's a condition that affects mostly boys and a very small part of our population. We knew we could do newborn screening and there was a therapy available, but it wasn't only realized until a few years ago to introduce newborn screening to help those families at the point of birth to know if their child was affected, and therefore start a different trajectory on how they planned for care for them and plan for if there was a medication or other supportive tools and resources available for them. So it's been extremely dynamic to see how things have evolved. And then now as you see medical and pharma medical technology advance as well into gene therapies. You're seeing news about gene therapy and it's a one time treatment and then the individual hopefully will not have be re redos in their lifetime. Along with that come challenges on that diagnosis piece to make sure they're eligible for the gene therapy. So again, through the device and technology sector, it plays a key role. In addition to the supportive care that goes on for some of these really severe conditions, people have some pretty dynamic needs and it's great to see how things are progressing, but it's still as equally as frustrating, whether you're on the manufacturer side or the family side, to see things be kind of slow sometimes. [00:06:15] Lindsey Dinneen: Yeah, of course. And you're dealing with a specific situation where many times-- please correct me if I'm wrong-- but it seems like many times there's these kinds of studies and conditions are not funded very well in terms of finding solutions to the problem. So how is that something that you, well, first of all, of course we're in a very interesting season of life right now. So how are you seeing funding evolve over the years for these different diseases that are a little bit more rare, and what can we all do in terms of even just awareness and understanding? [00:06:51] Sara Aswegan: Yeah, so that's a huge question. We could probably have about five conversations on this just to scratch the surface, Lindsey. I think if I reflect on the question on what we've seen around funding, I mean there are some wonderful, supportive grants available for the brilliant scientists we have around the world that have a curiosity. So making sure we can facilitate that ongoing academic environment to explore and test the hypothesis. And one of the things that you see coming along, and it's not really around-- I won't think about funding as just pure financial-- but it's the funding of the smarts that go around the table. You see a lot more collaboration amongst academia, industry governments coming together to help build and scale so that there's an awareness and understanding of a condition. I mean, a pediatrician could go through their entire career and never see a boy with Hunter Syndrome. It's just that rare. At the same time, and on the converse of that, if you're working in an industry where you do have access to more funds, the introduction of AI and looking at how we look at drug targeting, drug target selection, genetics and precision medicine have come along quite leaps and bounds in the last several years, but we're still not quite there. But you're seeing advancements with the different cell and gene therapies, having that precision medicine as an option. It's coming forward. The challenge is the size of studies are normally very small because the population is small. So thinking about patient recruitment, how can we help facilitate better identification of individuals that may be out there and not have received diagnosis because of the rarity of the condition? So looking at technology and advancement of integrated electronic health records up to and including, how do we look at the trial designs? And how do manufacturers, academics, industry, and agencies work together to think a little differently around even designing clinical endpoints for the studies that really are meaningful, that will make a difference. And how do you balance that, right? Correct risk benefit conversation, in the spirit of doing no harm. But if there's one chance and there's something available, how do you do that? And coming all the way downstream. If you think about where the organizations have advanced their thinking, their approach, and put funds behind, it's also that ongoing care of the individuals. If you look at the upstream, the types of tests that are available. It could be cancer, it could be the area I am so passionate about in genetic disorders, but it can also be thinking about the workflows that come into play in helping facilitate consistency of care across state borders, across country borders. It's a key piece that are really advancing in real time, but we're still trying to overcome the hurdles that are real. And that's things around data privacy. How do we navigate that in a really meaningful way with the right ethics and integrity. If we think about the regulators, this isn't a huge anti-infective or cardiac study that's ongoing, that there are gonna be tens of thousands of people. So how can we think a little bit differently on advancing the care. In the area I'm working in, Lindsey, especially with some of these individuals that are kids, if they don't get access to care by a certain age point, their window of treatment has closed. And so what could we do to help facilitate earlier diagnosis and then that advanced care. And so I think we can see a lot of really good intentions, and I think the most beautiful thing is even the collective gathering of different patient organizations that have a shared interest of a disease coming together and also helping raise research funds to help support the scientists that have a hypothesis on something that may really make a difference and may matter. [00:10:21] Lindsey Dinneen: Yeah. Yeah. Okay, so, there has been so much innovation in the last few years-- of course, even before that, but it seems to be extremely exciting in the last few years-- especially things like CRISPR and all sorts of new technologies emerging. What are some of the exciting trends that you're seeing in this space specifically that give you hope as you continue to look forward and look for solutions? [00:10:45] Sara Aswegan: I think for me, I mentioned, I touched on it lightly. I think it's that collective, that collaboration and the openness now. The FDA has advanced the way that they think and engage with agencies as well as industry partners. And so what I mean by that, Lindsey, is they're not just engaging with the scientists or with the manufacturers, the drug developers. They're also bringing patients in. And so that collaborative environment, they're even beginning conversations when there's discussion on clinical trial design to understand what really matters. Is it a six minute walk test or is it something around real behavioral or other abilities that can be learned and retained over time that help benefit the quality of life? If you're not gonna be able to cure something, what's really important at that patient front to help facilitate something meaningful. So I think that type of conversation also with the agencies looking at, there was an amazing session held in Europe recently in the mucopolysaccharidosis or the lysosomal storage disease area, looking at advancements of science and saying, can we look at biomarkers alone and create that relationship and understanding there is a clinically meaningful impact if we can address this biomarker. And so, companies like Ultragenyx have really pushed to have that conversation and dialogue and have a drug filed now that's under review based on biomarker endpoints alone, where five years ago, you would never have imagined that being possible. [00:12:12] Lindsey Dinneen: Yeah. Yeah. You touched on something that I would really love to explore a little bit deeper, and that is, when there's a situation that right now we don't have a cure for this disease-- and, you know, obviously we're still working towards it-- but if we don't have a cure, but we are trying to improve the quality of life, how do you balance that in your specific field in terms of: obviously you want the patients to live the best quality of life that they can while balancing so many other, and I don't mean this in a callous way at all, just from a practical perspective, balancing all of these other considerations and things that are also desiring funding and all those competing priorities. So how do you balance that? How, how does that come into play? [00:12:57] Sara Aswegan: So that's a big one. It's a tough one. And I'll oversimplify it and just say data. And what I mean by that, Lindsey is really looking at, with the technology at our fingertips, regardless of the geography you're living in, there's a lot of meaningful information that can be captured. And it's not, again, around one aspect of a disease, but it's the totality of health. So really looking at what could be possible in capturing, is it around energy levels, activity levels. And you'll see that oftentimes in play with the gene therapy, for example, when it's administered, you may have up to 15 years of follow up that you're capturing specific data points. But even in advance of a drug approval, and an area I am also equally passionate about, is access to unlicensed medicines for individuals that can't travel to a clinical trial site and could benefit from an investigational therapy, how do we do that with the right balance in place? And part of that is data and having the willingness of a participant or family member to be so consented in and participating in the study for their child to share that data and share that real world data or real world evidence so that you can measure back and show what impact that drug or treatment or intervention has been having on the individual. So I think it's around that and figuring out how we can overcome some of the complexities and challenges that are real. Not everyone has electronic health records. There's still lots of paper-based offices out there. But in the meantime, there's a lot of advancements in technology. So how do you appropriately use that, that it's also not overburdensome for the individual, for the family as well, that you're doing what really matters and measuring back and having the right conversations with the individuals affected, the investigators, the clinicians, but then the regulators, and going back and sharing why this can be something to help substantiate. It's not your standard phase 1, 2, 3 clinical trial design. That's, yes, there's rigor, but it's a different way of looking at using data to help us advance our understanding of a disease and what's needed by the individual affected. [00:14:53] Lindsey Dinneen: Yeah. So, so when you're speaking with these families and or-- well, first of all, let me actually back up. Do you have direct communication with some of these families and patients that you're working with? [00:15:04] Sara Aswegan: Yes. [00:15:05] Lindsey Dinneen: Yeah. And so when that happens, how. How is it for you? I mean, this is such a challenging area that you have devoted your life to and to, and I'm so impressed with that. And, you're doing the work that's helping save lives and make a difference. But that must be really challenging from a personal level to have these difficult conversations. So how do you balance that as a practitioner and somebody who's desiring to help, but you also have this real life compassion and human being that you're trying to help? [00:15:38] Sara Aswegan: It's tough and it's tremendously rewarding. At the same time, I have so many patient stories I can share with you of meeting them and meeting 'em where they are. I made a trip to Sao Paulo, Brazil once, Lindsey, and met a family that were living in the favelas there, and their aim was to help raise awareness for Hunter's Syndrome because their son had been undiagnosed. They knew something was wrong. He was nonverbal. He had some physical presentation that you could understand. There was something going on, but the technology wasn't there for them. The access to the care center wasn't there for them to get a diagnosis. They were taking buses for hours to different clinics to figure out what's wrong with our son. And he finally received a diagnosis of Hunter Syndrome and they wanted to share the photos because kids with Hunter Syndrome do have some different dysmorphism. So there's something that's strange. They have a bossy forehead, or their bridge of their nose is a little different. Their bellies might be a little bit bigger. So if you start looking at all of these different clues and putting it together, you might suspect and go-- there's other things going on, for sure. So I'm oversimplifying this. However, getting a diagnosis for him by just raising awareness to other families of the physical presentation and what their experience was extremely meaningful for them. And on balance, a family in Florida that I met and their son was diagnosed at age 18 months because their grandmother had seen a program on Mystery Diagnosis and said, "That sounds like my grandson." And so creating the conversation and meeting people where they are is really important because you may have some individuals that are very aware of how drugs are developed and all of the rigor that goes through that to then others that just they don't understand that some drugs are intended for a specific indication, specific population, and helping explain why their child may not be eligible for a particular study. It's tough, and that's not my responsibility, but the clinical teams and the clinicians that are having those conversations. So it's listening and really coming with a open heart and mind and having empathy to help figure out how can you educate. It's even moving into gene therapy. What does gene therapy actually mean? What are the risks? I'm afraid this sounds like it's something so futuristic. What will this mean for my son or daughter in 10 years from now? And, we may not have all of the answers, but you know, science has advanced and it's that risk benefit that you have to exercise. But really it's that coming with compassion and a listening ear and understanding and being honest. And if I can't help, maybe there's someone else that can help or there's a, did you know, there's a clinic here or a center there and helping that network stay connected and thrive is really important. And also being their voice, Lindsey, I mean, we can, we have an opportunity on our pharma, biomedtech side of the world that we can share what we've observed and try to apply that as we come to work every day and think about that family we met in Brazil or in Boston or in Florida or in, you know, Frankfurt, and whatever they may be experiencing. So it's being their advocate in other areas as well. [00:18:34] Lindsey Dinneen: Yeah, exactly. So with what you deal with, I am wondering what kinds of misconceptions or myths do you often encounter that are interesting and yet you would prefer to correct so that those of us in the general population are more informed? [00:18:52] Sara Aswegan: That's a good one. So I think having worked in the rare disease space, one of the biggest scrutinies there, there's on two sides of the coin. One is around diagnosis and why we can't do more around diagnosis. And sometimes the science is just not there yet. So again, to some of these experiences, like the story of the family in Brazil, it may not be about a blood test. It may be about a physical appearance and helping people piece things together. I think on the other end is at the point of delivery of the diagnosis and then if there is a treatment or intervention that can be taken, and not everyone has the same principle in their heart. There are companies that are motivated for different reasons, but certainly the big topic is are around drug prices, whether it's a gene therapy or a chronic lifetime medication, of how do we navigate that and how do we navigate that in a better way? And I think we have to start looking as an industry, as a community of people, of how do we address that? The cost of doing a clinical trial is tremendous. It's hugely expensive. Does it warrant though huge price tags on drugs forever in perpetuity? What's that right balance? And I think having a level of social responsibility and looking at alternatives. And so imagine if we could reduce the time for clinical studies for requirements because we're able to look at other data. Things like the biomarker approach and the follow on real world data that could be captured, could that help us in the total overall offering and the cost to the overall health system? Maybe. I think that as an industry, every company operates with different principles and wanting to do best for the patient community. Some are more profit driven than others, and so that's a reality, and it's one that I get so often at dinners with friends or in personal conversations, professional conversations, and it's a tough one. At the same time, a study of 60 individuals could be double digit millions of dollars. Just the cost of facilitating the study, the production costs of some of these highly technical compounds of different therapies also becomes a factor. So you have to put all these pieces together and really explore what's driving that. [00:20:57] Lindsey Dinneen: Yeah, of course. And yes, I'm sure that's a really difficult conversation to have too, when you're especially working directly with patients and trying to explain all of that and that's a lot. That's a challenge. [00:21:10] Sara Aswegan: Yeah. Yeah. [00:21:11] Lindsey Dinneen: But on the flip side, you know, of course the work that you do makes a huge impact, and I'm wondering if there are any stories that come to mind that just really reinforced to you, "You know what? I am in the right place at the right time, in the right industry." [00:21:25] Sara Aswegan: Absolutely. And I think it goes to, I touched on it very briefly, and there are people that aren't living in near major cities, near major medical centers, and that should not make them obsolete from receiving the best care. And there are two things that have happened and partly because of the pandemic, but also partly because of the willingness to educate and have that connected community amongst clinicians, is around that access to unlicensed medicine and finding pathways that it's not just because a doctor says your son or daughter needs this medication. I'm going to reach out to the manufacturer to see if I can get access because they're not near a clinical trial site or they don't wanna participate, or they're unable to participate in a study. But finding means to do that. And there have been some really creative ways that clinicians have been able to do that, of setting up qualified treatment centers where the individual can go to receive the treatment and then that continuity of care is provided then over the life of their disease. It's something that's become real and meaningful, and you would be shocked at the number of individuals around the world that are receiving access to medicines that normally might have only 10 years ago been available if you were living in the Western Europe or the United States because studies weren't conducted in their country and so there's no pathway for access that is all changing. Those dynamics are changing. It takes a team of people, though. It takes regulators, it takes lawmakers, it takes industry. It takes our logistics teams to be sure if something's stored at cold chain, that that product is delivered in the right context at the right time, just in time for that patient to receive it. So it's a complex challenge, but it's one that we've seen serve individuals in a really meaningful way. And without that, they wouldn't have, they wouldn't have another option. [00:23:11] Lindsey Dinneen: Yeah. So having that impact and just being able to reinforce in those moments of maybe when it's especially difficult or you're especially frustrated like, "Oh my gosh, I wish I could help X, Y, and Z," at least you can look back and go, "Yes, but look at all this that we are doing." [00:23:26] Sara Aswegan: You know, Lindsey, also it's that education piece and being curious and asking questions. The scientific community and one of the lead leaders in the NPS community is in North Carolina, Joe Munzer. Dr. Joe Munzer, he's brilliant. And one of the initiatives that we started was something called a masterclass. And so with Dr. Munzer and seven or eight other clinicians from around the world, we literally went on an educational program around the world. And some of the individuals that had just come out of their postgraduate work, pediatric geneticists or neurologists meeting the number one or two people that know this space so well, being mentored by them. And now those individuals are facilitating their class, the same type of class in their local language to their local communities and creating that level of education and awareness. I mean, it's just to see that real impact over time. I actually get goosebumps just thinking back on the impact that has had. And you've got a community of clinicians that they're, I mean, there's a lot of needs still to study medical genetics. And so hopefully we have individuals that are scientifically interested and will continue that that journey so that they can be the next teachers across borders. That makes the difference. [00:24:37] Lindsey Dinneen: Yeah. Absolutely. Wow. Yeah. Thank you for sharing that. I was also getting goosebumps just listening to it because that's incredible ripple effect that you had and continue to have. That's amazing. [00:24:47] Sara Aswegan: Yeah. Yeah. [00:24:47] Lindsey Dinneen: Yeah. Oh man. Okay. Well, I could talk about this for a long time, but pivoting the conversation a little bit, just for fun. Imagine that you were to be offered a million dollars to teach masterclass on anything you want. It can be within your industry, but doesn't have to be. What would you choose to teach? [00:25:05] Sara Aswegan: Wow. That is a great question, Lindsey. A masterclass-- a million dollars-- a masterclass on anything I would want. I would be drawn to some of the advancements we're seeing in gene therapies, but I think that would be, I wanna try to serve a broader population. Do you know? I think it's, I think if I could look, I would do something around looking back on some of these, if you will use cases and best practices, to share those learnings, just because we know the impact that it will have and has had and continues to have. And not just on the scientific community, but it ripples down into the patient communities of asking that question of "what can be possible, how can we together." Instead of " no," it's actually, "yes and" or "no and" we hear something else, another construct. And really breaking it down to really enforce what I've talked about on several moments during our conversation today is it can't just be the manufacturer, the, or the developer. It can't just be academia. It can't just be health authorities or regulators. It's a collective community and it has to include that patient within that conversation to help for that learning and advancement and understanding. And so I think it's something around that, the best practices, use cases, and really things that made a difference. Meeting people where they are of a good understanding of the science, not good understanding of the science, that crosses all levels. Drug development overall. The total continuity of care for my individual affected. It's not just about a drug, but it's about assistive devices or other tools that they can have a better life. And so being really thoughtful about that I think would be something that would be really amazing. That it's actually captured and taught back. [00:26:47] Lindsey Dinneen: Yeah, absolutely. That would be a fantastic masterclass. All right, and then how do you wish to be remembered after you leave this world? [00:26:56] Sara Aswegan: Well, at some point I know my husband will admit I have the best sense of humor. [00:27:01] Lindsey Dinneen: Yes. [00:27:02] Sara Aswegan: I think for me, Lindsey, I really would hope that people would say an open heart, a generous heart, and just a connector of people, personally, professionally. It takes two seconds to be kind and open and nobody has all the answers. So help people connect with others and be willing to say, "How can I help?" [00:27:20] Lindsey Dinneen: Yeah, absolutely. Yeah. And then final question, is one thing that makes you smile every time you see or think about it? [00:27:31] Sara Aswegan: I just came in from my garden and I have to say, seeing my advancement of fostering my garden and I've got things blooming now. There is hope. [00:27:40] Lindsey Dinneen: I love that. I feel that way every time I somehow succeed in keeping a plant alive. [00:27:45] Sara Aswegan: There is hope. It's really around the simple things, right? That's it. [00:27:49] Lindsey Dinneen: Yeah, absolutely. Now, for any of our listeners who are excited to get to know about you and your work a little bit more, can you just share briefly what is it that you do right now to help companies succeed and how can people get in touch with you? [00:28:02] Sara Aswegan: Thanks, Lindsey. So I am currently doing some advisory board work for a couple of consultancies as well as helping some small and mid-sized biotechs figure out their pathway and how they go to market. How do they facilitate access to unlicensed medicines? I'm passionate about the rare space, so I'm serving also on a couple of special projects on getting drugs and diagnostics into low middle income countries. And it's something I'm very passionate about and I've got a great network of people. So if I can't help, I'm always happy to say, "Not me, however, I know someone you should talk to." And to get in touch, it's not easy to spell, but it's www.saraaswegan.com. And again, if I can't help, I might know someone who can. And I think it's just, it's really good to share our knowledge and experience and really make a difference however we can. [00:28:47] Lindsey Dinneen: Yeah. Absolutely. Well, thank you, Sara. This has been absolutely incredible to learn from you, to hear about your story. So thank you for sharing and being open. I really appreciate that. And my goodness, I just wish you the most continued success as you work change lives for a better world. [00:29:03] Sara Aswegan: Thanks Lindsey, and thanks for everything you're doing. Really, hats off. Thanks a million. [00:29:07] Lindsey Dinneen: Of course, and have the best rest of your day. And thanks also to our listeners for tuning in. If you're feeling as inspired as I am right now, I'd love it if you shared this episode with a colleague or two and we'll catch you next time. [00:29:22] Ben Trombold: The Leading Difference is brought to you by Velentium. Velentium is a full-service CDMO with 100% in-house capability to design, develop, and manufacture medical devices from class two wearables to class three active implantable medical devices. Velentium specializes in active implantables, leads, programmers, and accessories across a wide range of indications, such as neuromodulation, deep brain stimulation, cardiac management, and diabetes management. Velentium's core competencies include electrical, firmware, and mechanical design, mobile apps, embedded cybersecurity, human factors and usability, automated test systems, systems engineering, and contract manufacturing. Velentium works with clients worldwide, from startups seeking funding to established Fortune 100 companies. Visit velentium.com to explore your next step in medical device development.

From the BBC World Service: The decision at Toyota in Brazil comes after intense storms halted production at its factories in the state of Sao Paulo, and many of the workers will be paid in full during the closed period. Hackers have attempted to recruit the BBC's cyber correspondent into helping them infiltrate the broadcaster's systems. And has Canada lost in the trade war with the U.S.? Over the past month, it's removed billions of dollars in retaliatory tariffs on American goods.

From the BBC World Service: The decision at Toyota in Brazil comes after intense storms halted production at its factories in the state of Sao Paulo, and many of the workers will be paid in full during the closed period. Hackers have attempted to recruit the BBC's cyber correspondent into helping them infiltrate the broadcaster's systems. And has Canada lost in the trade war with the U.S.? Over the past month, it's removed billions of dollars in retaliatory tariffs on American goods.

26-09-25 - Programa Seguinte Apos Eliminacao do Sao Paulo na Libertadores - Programa Nr 6909

Joining the show today is Candice Smithyman, an international prophetic revivalist, author and host of the Glory Road TV show, Rebekah Green,an interpreter of dreams for leaders, including government officials, and Lu Batchman, leader/president of the A Million Women Brazil movement! Hear about the upcoming event One Million Women - Brazil, October 25 in Sao Paulo, Brazil! Learn the significance of the timing and dates of the event, and why this is a critical time for Brazil! Go to amillionwomen.org for more information.

Nathan Sexer is the head of Devcon and Devconnect at Ethereum Foundation, and Romina Sejas runs ETH Kipu - host of the annual ETH Latam eventIn this conversation we discuss how Latin America will be the center of the crypto universe this November when Devconnect, the premier Ethereum developer gathering, comes to Buenos Aires and ETH Latam comes to Sao Paulo. These events will be a coming of age moment for the region as the crypto world grasps the importance and potential of these technologies in places like Brazil and Argentina-------------------------------------------------------------------

Join Kate Stanton Melendez for an interview with soft sculpture artist, performance artist, and college professor Kelly Boehmer.    Kelly has exhibited and performed her work nationally and internationally in over 175 exhibitions including shows in Baltimore, Dallas, Miami, New York City, New Orleans, Pittsburgh, San Juan, Sao Paulo, Brazil, Gimpo-si, Gyeonggi-do, Korea and Sarajevo, Bosnia and Herzegovina.  She received her BFA in Studio Art at the Maryland Institute College of Art and her MFA in Studio Art at the University of South Florida. She is a member of the performance art band, Glitter Chariot. Kelly is a Professor of Foundations Studies at Savannah College of Art and Design, in Savannah, GA.   Boehmer's soft sculptures combine tragic humor with a celebration of the hidden beauty found within anxiety. Her creatures serve as metaphors for personal struggles with anxiety and aging. She finds humor in her attempts to become "comfortable in my own skin" and to navigate these challenges, particularly with social anxiety. Though the imagery may appear grotesque, with flayed and molting forms, these creatures represent growth, transformation, and positive change. She uses glittery sheer fabrics and vivid faux fur, to contrast difficult emotions with inviting textures. This creates a tension between attraction and repulsion, softening the rawness of the subject matter and making it more approachable for the viewer. Many of her works draw inspiration from iconic pieces in art history, such as the Unicorn Tapestries, the Laocoön Group, Lion Hunt of Ashurbanipal, and The Arnolfini Portrait. Her aggressive hand-sewing technique is similar to an expressive line in drawing. A key element of the process involves repurposing materials from previous sculptures, cutting them up after an exhibition and combining them with upcycled taxidermy. This gives the materials a “second life,” creating a layered history of growth and change embedded within the pieces themselves.   Check out Kelly's work here: https://www.kellyboehmer.com/ Kelly Boehmer (@kelly.boehmer) • Instagram photos and videoshttps://www.instagram.com/kelly.boehmer/?hl=en   Buy Kelly's work from Cindy Lisica Gallery in the Atlanta Art Fair: https://artcloud.market/show/cindy-liscia-gallery-atlanta-art-fair   See her husband Chuck Carbia's work here: https://www.chuckcarbia.com/

U.S. interventions in Brazilian politics since the 19th century & Bolsonaro's 27-year prison term. ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠

In 2012, inside a quiet luxury apartment in Sao Paulo, a couple sat down to confront their marital trust issues. What began as a tense conversation between husband and wife quickly spiraled into violence and horror and what followed left an entire nation stunned. Was this the desperate act of a woman defending herself from abuse or the calculated crime of a cold-blooded killer?Sources:Elize Matsunaga: Once Upon a Crime. Netflix, 2021.Newsweek. “Who Is Elize Matsunaga? The True Story Behind Netflix's Once Upon a Crime.” July 7, 2021.Esquire. “Elize Matsunaga Shot and Dismembered Her Husband—Here's Where She Is Now.” July 14, 2021.The Independent. “Netflix's Elize Matsunaga: Once Upon a Crime — the true story.” July 8, 2021.Radio Times. “True story behind Netflix's Elize Matsunaga: Once Upon a Crime.” July 7, 2021.Folha de S.Paulo. “Em vídeo, Elize Matsunaga conta como matou o marido.” August 26, 2012.TV Globo — Fantástico. “Vídeo de Marcos com outra mulher pode ter provocado briga.” 2012.TV Globo — Fantástico. “Julgamento de Elize Matsunaga.” 2016.BBC News Brasil. “Quem é Elize Matsunaga, condenada por matar e esquartejar o marido.” July 2021.General Mills. “General Mills to Acquire Yoki Alimentos S.A.” Press release, May 24, 2012.This Week's Episode Brought to You By:Shopify - $1 per month trial - http://shopify.com/lovemurderHiya - 50% off your first order - http://hiyahealth.com/lovemurderFind LOVE MURDER online:Website: lovemurder.loveInstagram: @lovemurderpodTwitter: @lovemurderpodFacebook: LoveMrdrPodTikTok: @LoveMurderPodPatreon: /LoveMurderPodCredits: Love Murder is hosted by Jessie Pray and Andie Cassette, researched by Sarah Lynn Robinson and researched and written by Jessie Pray, produced by Nathaniel Whittemore and edited by Kyle Barbour-HoffmanSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

El juez Alexandre de Moraes, instructor del juicio contra el expresidente brasileño Jair Bolsonaro por golpismo, ha propuetso una pena de 27 años y tres meses de prisión para el exmandatario. Analizamos qué supone con Claudio Gonçalves Couto, doctor en Ciencia Política y profesor de la Fundación Getulio Vargas de Sao Paulo.Escuchar audio

A huge demonstration has taken place in the Brazilian city of Sao Paulo to denounce the Supreme Court trial of the former president, Jair Bolsonaro. He's accused of plotting a failed military coup against President Luiz Inacio Lula da Silva after losing his bid for re-election nearly three years ago. He denies the charges. The court is widely expected to convict Mr Bolsonaro in the next few days. Also: Zelensky condemns "ruthless attack" after Russia hits main government building in Kyiv, and have you seen the Blood Moon - a total lunar eclipse? The Global News Podcast brings you the breaking news you need to hear, as it happens. Listen for the latest headlines and current affairs from around the world. Politics, economics, climate, business, technology, health – we cover it all with expert analysis and insight. Get the news that matters, delivered twice a day on weekdays and daily at weekends, plus special bonus episodes reacting to urgent breaking stories. Follow or subscribe now and never miss a moment. Get in touch: globalpodcast@bbc.co.uk

The Chiefs open the 2025 NFL Season as a 3-Point favorite against the Chargers in Sao Paulo, Brazil. It's time to actually break down the game.Jeff Chadiha (NFL Network/NFL.com/@JeffriChadiha), Sam McDowell (Kansas City Star/KCStar.com/@SamMcDowell11) and Soren Petro (Sports Radio 810 - WHB/810whb.com/@SorenPetro) welcome James Palmer (The Atheltic's Scoop City & 89 with Steve Smith Podcast/@JamesPalmerTV) to fill in for Sam (In Brazil with the Chiefs) on the Podcast. They discuss…- Biggest challenge the Chargers present is..- Will the Chiefs go downfield?- Expectations for Simmons and Suamataia are…- Impact on Chargers losing Slater?- Have the Chargers put enough around Justin Herbert?- Will the Chiefs DL hold up?- Can LA expose the Chiefs secondary?- Keys to the game?- Predictions!!!

Daniel Jeremiah, Bucky Brooks and Rhett Lewis kick off the show previewing the first game of the 2025 NFL season as the Cowboys take on the Super Bowl champion Eagles. They analyze how the loss of Micah Parsons will impact Dallas’ chances of slowing down the Eagles dynamic offense and break down what the next step of Vic Fangio’s defense will look in 2025. (1:27) Then, they head to Sao Paulo, Brazil where the Chargers host the reigning AFC Champion Kansas City Chiefs.. The guys detail how Patrick Mahomes continues to elude defeat despite Justin Herbert seemingly doing his part and analyze what the Chargers need to do different to leave Brazil with a victory. (13:26) Move the Sticks is part of the NFL Podcasts Network.See omnystudio.com/listener for privacy information.

In the latest episode of the NFL Fantasy Football Podcast, Marcas Grant, Michael F. Florio, and LaQuan Jones preview the two kickoff games on Thursday and Friday night with the Cowboys visiting the Eagles and the Chiefs facing the Chargers in Sao Paulo, Brazil. (2:14) Then, they discuss the biggest fantasy questions surrounding the rest of the Week 1 matchups. (7:02) Finally, each host shares their Must-Start of the Week (12:15) and Sleeper of the Week! (21:20) The NFL Fantasy Football Podcast is part of the NFL Podcast Network.See omnystudio.com/listener for privacy information.

Seven months after losing the Super Bowl, the Chiefs are back in action with the regular-season opener on Friday against the Los Angeles Chargers, in Sao Paulo, Brazil of all places. On SportsBeat KC, The Kansas City Star sports podcast, beat writer Pete Sweeney breaks down what to expect from a team bidding for its fourth straight Super Bowl appearance. First, we review the roster moves over the past week that helped shape this team. After a break, we look ahead at how standouts like Patrick Mahomes, Travis Kelce, Chris Jones and Isiah Pacheco will fare. Also, we submit our final record predictions. Learn more about your ad choices. Visit megaphone.fm/adchoices